Evidence map›Paper›PMID 29713318›Full record

ReviewFrontiers in immunology2018

Complement Activation in Inflammatory Skin Diseases.

Jenny Giang, Marc A J Seelen, Martijn B A van Doorn, Robert Rissmann, Errol P Prens, Jeffrey Damman

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 121 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jenny GiangDepartment of Pathology, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands.
Marc A J SeelenDepartment of Nephrology, University Medical Center Groningen, Groningen, Netherlands.
Martijn B A van DoornDepartment of Dermatology, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands.
Robert RissmannCenter for Human Drug Research, Leiden, Netherlands.
Errol P PrensDepartment of Dermatology, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands.
Jeffrey DammanDepartment of Pathology, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands.
Erasmus MC · NLCentre for Human Drug Research · NLUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The complement system is a fundamental part of the innate immune system, playing a crucial role in host defense against various pathogens, such as bacteria, viruses, and fungi. Activation of complement results in production of several molecules mediating chemotaxis, opsonization, and mast cell degranulation, which can contribute to the elimination of pathogenic organisms and inflammation. Furthermore, the complement system also has regulating properties in inflammatory and immune responses. Complement activity in diseases is rather complex and may involve both aberrant expression of complement and genetic deficiencies of complement components or regulators. The skin represents an active immune organ with complex interactions between cellular components and various mediators. Complement involvement has been associated with several skin diseases, such as psoriasis, lupus erythematosus, cutaneous vasculitis, urticaria, and bullous dermatoses. Several triggers including auto-antibodies and micro-organisms can activate complement, while on the other hand complement deficiencies can contribute to impaired immune complex clearance, leading to disease. This review provides an overview of the role of complement in inflammatory skin diseases and discusses complement factors as potential new targets for therapeutic intervention.

Indexed as

AnimalsAutoantibodiesComplement ActivationComplement System ProteinsDermatitisHumansImmune Complex DiseasesInflammationMolecular Targeted TherapySkinAutoantibodiesComplement System Proteinsbullous pemphigoidcomplementdermatologyhidradenitis suppurativainnate immunitylupus erythematosuspsoriasisskin diseases

Identifiers

PMID29713318
PMCPMC5911619
OpenAlexW2801488687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.